The use of 1.5-anhydroglucitol for monitoring glycemic control in islet transplant recipients

Eduardo Moraes Leao Peixoto, Nujen Colak Bozkurt, Shari Messinger, Maria Isabel del Olmo García, Vincenzo Lauriola, Andrea Corrales, Eva Herrada, Camillo Ricordi, Rodolfo Alejandro

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


We evaluated whether 1,5-anhydroglucitol (1,5-AG) (GlycoMark®), a test for measuring postprandial glucose and glucose variability, could be a tool for assessing short-term glycemic control in islet cell transplant (ICT) subjects. Data of 21 subjects, with type 1 DM and allogenic islet transplantation, who had concomitant fructosamine, HbA1c, 1,5-AG (n = 85 samples), and capillary glucose self-monitoring measurements (n = 2,979) were analyzed retrospectively at different time points after ICT. A significant negative association was observed between 1,5-AG and HbA1c (p = 0.02), but not with fructosamine. When HbA1c was divided in quartiles as <5.6, 5.6–5.9, 5.9–6.2, and >6.2, a decrease of an estimated 0.70 ± 0.30 μg/ml in 1,5-AG was associated with each quartile of increase in HbA1c (p < 0.0001). There was a significant decline of 1.64 ± 0.3mg/dl in postprandial glucose values for each 1 unit increase in 1,5-AG (p < 0.0001). For those with HbA1c ≥6.0% when 1,5-AG was ³8.15 μg/ml, the mean estimated glucose level was 103.71 ± 3.66 mg/dl, whereas it was 132.12 ± 3.71 mg/ dl when 1,5-AG was <8.15 μg/ml. The glucose variability (Glumax - Glumin) in subjects with 1,5-AG <8.15μg/ml was 46.23 mg/dl greater than the subjects with 1,5-AG ≥8.15 μg/ml (HbA1c ≥ 6.0%). There was no significant association between GlycoMark and glucose variability where HbA1c <6%. 1,5-AG significantly associated with postprandial glucose levels and glucose variability in ICT recipients with near-normal HbA1c (6.0–6.5%) levels. These findings suggest that 1,5-AG can be used to differentiate those ICT subjects with higher glucose variability despite having near-normal HbA1c. However, prospective studies are needed to evaluate the association between GlycoMark levels and the parameters of graft dysfunction/failure.

Original languageEnglish (US)
Pages (from-to)1213-1219
Number of pages7
JournalCell transplantation
Issue number10
StatePublished - 2014


  • Glucose variability
  • Glycemic control
  • GlycoMark
  • Islet transplantation

ASJC Scopus subject areas

  • Cell Biology
  • Transplantation
  • Biomedical Engineering


Dive into the research topics of 'The use of 1.5-anhydroglucitol for monitoring glycemic control in islet transplant recipients'. Together they form a unique fingerprint.

Cite this